A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
This is an early-stage research study, sometimes called a Phase I trial, investigating a new treatment called belantamab mafodotin for a type of blood cancer called multiple myeloma. This particular study is for people whose multiple myeloma has come back after treatment or isn't responding to current treatments. Researchers want to understand how this new medicine works in the body, especially in people with different levels of liver health. The main goal is to find a safe dose and see how the body handles the drug when the liver isn't working perfectly. This information is crucial for planning larger studies in the future and making sure new treatments are as safe and effective as possible for everyone.
At a glance
What is this study about?
This study is a very early step in testing a new medication for multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, a kind of white blood cell found in the bone marrow. When we say 'relapsed or refractory', it means the cancer has either returned after being treated, or it hasn't responded to previous treatments.
The new medication being tested is called belantamab mafodotin. This study is specifically designed to understand how this medicine behaves in the body, particularly focusing on how it is processed by the liver. The liver plays a big role in breaking down medicines, so it's important to know if liver health affects how this drug works or if it changes the amount of drug in the body.
By carefully studying how belantamab mafodotin is handled in people with healthy livers and those with some liver impairment, researchers can figure out the best and safest way to use this medicine in future, larger studies. This helps to ensure that new treatments are developed responsibly and can eventually benefit as many patients as possible.
Key takeaways
- This is an early-stage study for a new multiple myeloma treatment.
- It's for people whose multiple myeloma has come back or isn't responding to current treatments.
- The study looks at how the new medicine works in people with different liver health.
- It aims to find a safe dose and understand side effects.
- Participation involves regular hospital visits for tests and medication.
- You can stop participating at any time.
Who may be eligible?
This study is looking for adults who are 18 years old or older. Both men and women can take part. A key requirement is that you have been diagnosed with multiple myeloma that has either come back after treatment or isn't responding to current treatments.
Because this study is particularly interested in how the medicine affects people with different liver conditions, there will be very specific medical checks to see if your liver is currently healthy or if you have some liver problems. This helps the researchers understand the medicine better.
There will be other medical checks and a review of your health history to make sure this study is right for you and that taking part would be safe. Your study doctor will discuss all these details with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have multiple myeloma that has relapsed (come back) or is refractory (not responding to treatment)?
- Are you able to attend regular hospital visits and follow study instructions?
- Are you comfortable potentially receiving a new, experimental medication?
What does participation involve?
If you decide to take part in this study, you will have regular visits to the hospital or clinic. These visits will include various tests such as blood tests, urine tests, and possibly other scans or checks to see how you are responding to the medication and how your body is handling it. You will receive the study medication, belantamab mafodotin, as planned by the research team.
Throughout the study, the research team will closely monitor your health and any side effects you might experience. The total duration of your participation will depend on how you respond to the treatment and the study plan, but it will involve ongoing check-ups and follow-up once treatment ends to understand the long-term effects.
Potential risks and benefits
Locations (1)
- —UnverifiedGreece
Common questions
What is multiple myeloma?
Multiple myeloma is a type of cancer that starts in your plasma cells, which are a kind of white blood cell found in your bone marrow.
What does 'relapsed or refractory' mean?
It means your cancer has either come back after being treated, or it hasn't responded well to previous treatments.
What is a Phase I study?
A Phase I study is one of the first steps in testing a new medicine in people. It mainly focuses on finding a safe dose and understanding how the body handles the medicine.
Why are they looking at liver function?
The liver helps process medicines, so researchers want to understand how this new drug works in people with healthy livers and those with some liver problems, to make sure it's safe for everyone.
Will I get this new medicine if I join?
Yes, if you meet the study requirements, you would receive the new medicine being tested, called belantamab mafodotin.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.